ArticleFrontiers in medicine2025

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.

Lei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.